Information in Relation to Annual General Meeting
Oxford, UK – 19 June, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today provides further details for the Group’s Annual…
Oxford Biomedica provides update on ophthalmology programmes out-licensed to Sanofi
Oxford, UK – 9 June, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, has been informed by Sanofi that following completion…
Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this…
Oxford Biomedica Appoints Dr. Roch Doliveux as Non-Executive Chairman
Oxford, UK – 1 June, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, is pleased to announce that Dr. Roch Doliveux…
Oxford Biomedica Signs Clinical & Commercial Supply Agreement with AstraZeneca, for manufacture of COVID-19 vaccine candidate
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this…
Oxford Biomedica 2019 Annual report and Accounts & AGM Notification
London, UK – 22 May 2020: Oxford Biomedica plc (“Oxford Biomedica”, “the Company” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the…
Oxford Biomedica receives MHRA approval for the first two manufacturing suites in Oxbox
Oxford, UK – 13 May, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announced today the successful outcome of their recent…
Preliminary results for the year ended 31 December 2019
Oxford Biomedica plcPreliminary results for the year ended 31 December 2019 Building the Group for future growth Oxford, UK – 6 May 2020: Oxford Biomedica plc (LSE: OXB), (“OXB” or…
Oxford Biomedica notes the announcement that Kymriah® has received FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Oxford, UK – 22nd April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, notes the announcement from Novartis that the US…
Notice of Results Update
Full Year Results to be Published on 6th May 2020 Oxford, UK – 16th April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and…
Oxford Biomedica joins Consortium to rapidly develop a COVID-19 vaccine candidate
Consortium led by Jenner Institute, University of Oxford Fast-tracked clinical trial of ChAdOx1 nCOV-19 vaccine candidate starts this month Oxford, UK – 8th April, 2020: Oxford Biomedica plc (LSE:OXB) (“Oxford…
Oxford Biomedica Signs License & Clinical Supply Agreement with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, for LentiVector® Platform for CAR-T and TCR-T Therapeutics
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this…